Real-world adherence to and persistence with emicizumab in people with hemophilia A using a national claims database

Key Points

• The research aims to evaluate adherence and persistence rates of emicizumab in people with hemophilia A in a real-world context.
• Analyzed national claims database
• Focused on patients who initiated emicizumab treatment
• Assessed adherence and discontinuation rates within the first year
• High adherence rates were noted among patients
• Low rates of discontinuation were observed during the first year of treatment